From: NK cell upraise in the dark world of cancer stem cells
Tumor type | Condition or disease | Origin of NK cell | Target | Status | Phase | Country | Clinical trial ID |
---|---|---|---|---|---|---|---|
Hematological malignancy | B-ALL | Haploidentical PB-NK | CD19 | Recruiting | II | Singapore | NCT01974479 |
B-ALL | Haploidentical PB-NK | CD19 | Completed | I | USA | NCT00995137 | |
Lymphoma and leukaemia | NK-92 | CD7 | Recruiting | I/II | China | NCT02742727 | |
Lymphoma and leukaemia | NK-92 | CD19 | Recruiting | I/II | China | NCT02892695 | |
Refractory B-cell lymphoma | Unknown | CD19 | Not recruiting | Early I | China | NCT03690310 | |
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Unknown | CD19 | Not recruiting | Early Phase 1 | China | NCT04639739 | |
Relapsed and refractory B cell malignancies | Unknown | Â | Recruiting | I/II | China | NCT04747093 | |
Refractory B-cell lymphoma | Unknown | CD19/CD22 | not recruiting | Early I | China | NCT03824964 | |
AML | NK-92 | CD33 | Completed | I/II | China | NCT02944162 | |
Lymphoma and leukaemia (relapsed/refractory B-cell malignancy) | Umbilical cord blood | CD19 | Recruiting | I/II | USA | NCT03056339 | |
Refractory B-cell lymphoma | Unknown | CD22 | Not recruiting | Early I | China | NCT03692767 | |
Lymphoma and leukaemia | Umbilical cord blood | CD19 | Withdrawn | I/II | USA | NCT03579927 | |
relapsed/refractory multiple myeloma | NK92 | BCMA | Recruiting | I/II | China | NCT03940833 | |
B-cell lymphoma, CLL | iPSC (FT596) | CD19 | Recruiting | I | USA | NCT04245722 | |
Solid tumor | Metastatic solid tumor | PB-NK | NKG2DL | Recruiting | I | China | NCT03415100 |
Glioblastoma | NK-92 | HER2 | Recruiting | I | Germany | NCT03383978 | |
Non-small cell lung cancer | NK-92 | – | Recruiting | I | China | NCT03656705 | |
Solid tumor | NK-92 | ROBO1 | Recruiting | I/II | China | NCT03931720 | |
Solid tumors | NK-92 | ROBO1 | Recruiting | I/II | China | NCT03940820 | |
Pancreatic cancer | NK-92 | ROBO1 | Recruiting | I/II | China | NCT03941457 | |
Epithelial ovarian cancer | PB-NK | Mesothelin | not recruiting | Early I | China | NCT03692637 | |
Castration-resistant prostate cancer/ | PB-NK | PSMA | Not recruiting | Early I | China | NCT03692663 | |
Solid tumor | NK-92 | MUCI | Recruiting | I/II | China | NCT02839954 |